Navigation Links
GeoVax Labs, Inc. Comments on Discontinuance of Merck's HIV Vaccine Trial
Date:9/24/2007

ATLANTA, Sept. 24 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX)

On September 21, 2007, Merck & Co., Inc. announced their candidate AIDS vaccine failed to provide protection in a human study designed to test for efficacy.

In this Merck trial involving high risk volunteers, an equal number of people received either placebo or AIDS vaccine. The independent Data Safety Monitoring Board recommended that the trial be stopped because it was not reaching its efficacy endpoints.

Merck has stopped further vaccinations but will continue to follow volunteers in the trial. The Merck trial was being carried out in conjunction with the HIV Vaccine Trials Network (HVTN), a prestigious trial network funded by the US National Institutes of Health.

Don Hildebrand, GeoVax's President and CEO, commented, "We, along with the rest of the scientific community, are disappointed in the clinical failure of Merck's HIV vaccine trial. We all share the same goal of finding a safe and effective vaccine to address the devastation of the HIV/AIDS epidemic. We, however, would like to take this opportunity to highlight important differences between our vaccine technology and the technology used in the Merck trial."

GeoVax AIDS vaccines advancing in human trials represent a significantly different vaccine approach, vaccine composition and results to date than the Merck vaccine.

1) Prototypes for the GeoVax vaccines were selected from a series of trials in non-human primates for their ability to protect against the development of AIDS when vaccinated individuals were administered an AIDS causing virus. At each major step along the development pathway, GeoVax vaccines providing the best protection against AIDS were moved forward.

2) GeoVax AIDS vaccines demonstrated excellent protective results in non- human primate models, much better protective results than reported for Merck's vaccine in similar models. GeoVax AIDS vaccines pro
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
3. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
4. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
5. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
6. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
7. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. New Flu Vaccine from PepTcell Could Provide Immunity Against All Strains of Influenza Virus
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. New Flu Vaccine From PepTcell Could Provide Immunity Against All Strains of Influenza Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... 2015  SynCardia Systems, Inc. has received FDA approval ... on the effective use of its 50cc SynCardia temporary ... The FDA approval will allow SynCardia to ... failure patients. Patients enrolled in this study will receive ... to a donor heart transplant. (Caution-In the United ...
(Date:3/31/2015)... March 31, 2015 MedSpring Urgent Care is pleased to ... Dallas/Fort-Worth area of Upper Greenville. The center – located ... Dallas location. Knox - Henderson ... the surrounding community since opening last fall. Additional Dallas ... Keller and Las Colinas neighborhoods this summer. ...
(Date:3/31/2015)... AVIV, Israel, March 31, 2015  Galmed Pharmaceuticals ... biopharmaceutical company focused on the development and commercialization ... of liver diseases and cholesterol gallstones, today announced ... 31, 2014. Fourth Quarter 2014 Highlights: ... featuring a keynote address by Professor Rohit Loomba, ...
Breaking Medicine Technology:FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 2FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 3FDA Approves Investigational Study for New Smaller SynCardia Total Artificial Heart 4MedSpring Urgent Care Opens New Upper Greenville Location in Dallas 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8
... ALBUQUERQUE, N.M., Sept. 2 Clinical Lab,Products ... BMOD),( http://www.biomoda.com ) and its proprietary early ... more promising advances in the cancer diagnostic,technology. ... makes particular,note of the assay,s simplicity that ...
... Invasive Surgery at St.,Luke,s-Roosevelt Hospital Center completes his ... benefiting from ,hidden scar, procedure, CUPERTINO, Calif., ... completion of a series of single port Lap-Band,procedures ... pain for,patients. Dr. Julio Teixeira at St. Luke,s-Roosevelt ...
Cached Medicine Technology:Clinical Lab Products Magazine Features Biomoda 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 2Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments 3
(Date:3/31/2015)... 2015 When SIGVARIS launched the EVERSHEER compression ... product launch to date. Women immediately fell in love with ... another reason to love EVERSHEER with the launch of a ... , Lavender mist pairs perfectly with a variety of navy, ... women looking to add a hint of spring to their ...
(Date:3/31/2015)... The report “Coagulation/Hemostasis Analyzer Market By ... (APTT, Prothrombin Time/INR, D-Dimer, Fibrinogen), Technology (Mechanical, Optical), ... and studies the major market drivers, restraints, opportunities ... the Rest of the world (RoW). , ... reach $3.58 billion by 2019 from $2.4 billion ...
(Date:3/31/2015)... 31, 2015 Safeware has ... Employers in Central Ohio, an awards program presented by ... winners of the awards program, held on March 10, ... to employee health, with outstanding health and wellness initiatives. ... to creating a healthy environment for their associates. Business ...
(Date:3/31/2015)... Spring Hill, FL (PRWEB) March 31, 2015 ... and Substance Abuse (CASA) at Columbia University states that ... arrested in the U.S. and enter state juvenile justice ... abuse problems, are under the influence of drugs or ... of these factors. Despite this high incidence of substance-related ...
(Date:3/31/2015)... Italy (PRWEB) March 31, 2015 A' ... the design project Bruker EVOQ by Daniel Dion has ... Design Award in Scientific Instruments, Medical Devices and ... EVOQ, Daniel Dion, the creative mind behind the award ... EVOQ MS - developed under the direction of Dr. ...
Breaking Medicine News(10 mins):Health News:Put Spring in Your Step with SIGVARIS’ Top Selling Sheer Hosiery Compression Therapy Brand 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 2Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 3Health News:The Global Coagulation Analyzers Market will be Valued at $3.58 Billion in 2019 - MarketsandMarkets 4Health News:Safeware Recognized as a Healthiest Employer in Central Ohio 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 2Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 3Health News:$14.4 Billion Annual Price Tag: Suncoast Rehab Center Questions Harsh Sentencing of Juvenile Drug and Alcohol Offenders 4Health News:Daniel Dion wins Golden in A' Medical Product Design Awards 2
... , RESTON, Va., Aug. 11 ... the digital world, today released a study of the online health ... online consumer activity. While the number of visitors to health insurance ... increase in the number of searches related to obtaining health coverage ...
... engineered white blood cells could include drug testing, researchers ... new technique that transforms embryonic and adult stem cells ... produce blood cells with specific defects for use by ... The method, devised by University of Wisconsin-Madison researchers, could ...
... study conducted at the Jefferson Headache Center at ... an investigational, orally-inhaled therapy is effective in treating ... for the orally-inhaled migraine therapy, LEVADEX, shows study ... pain, nausea and light and sound sensitivity when ...
... NewYork-Presbyterian Hospital/Weill Cornell Medical Center will create a New York ... treatment for elder abuse cases in the New York City ... focus on coordinating elder abuse cases, the Center has received ... Leslie R. Samuels Foundation and $75,250 from the FJC, A ...
... , WASHINGTON, Aug. 11 The Partnership to ... care provisions contained within health reform legislation passed out of committee. ... be improved to increase quality of care and reduce health care ... other legislation is introduced, specifically the Senate Finance Committee plan. , ...
... , , LAKE FOREST, Ill., Aug. ... leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug ... States. The medication is a generic version of Sanofi-Aventis, Eloxatin(R), which ... is one of the first generic versions of this drug to ...
Cached Medicine News:Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 2Health News:Health Insurance Provider Sites Attract Fewer U.S. Visitors as Unemployment Increases 3Health News:Stem Cell Advance May Further Disease Research 2Health News:NYC's first elder abuse center created by NYP/Weill Cornell in collaboration with community partners 2Health News:NYC's first elder abuse center created by NYP/Weill Cornell in collaboration with community partners 3Health News:Partnership to Fight Chronic Disease Analyzes Key Provisions in Health Care Legislation Released To-Date 2Health News:Hospira Launches Generic Oxaliplatin Injection 2Health News:Hospira Launches Generic Oxaliplatin Injection 3
Handheld Digital Retinal Camera...
Inquire...
Specifically for placing follicular units....
... are available in three styles ... available non-sterile and sterile, and ... Depending on the patient needs, ... or two implants (medial and ...
Medicine Products: